Schedule 13G ownership disclosure

4D Molecular Therapeutics Inc

Common Stock · CUSIP: 35104E100

Event date: 2025-09-30

Filing-level shares
3,062,596
Percent of class
6.6%
  • BlackRock, Inc.

    Shares: 3,062,596 · Class: 6.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002012383-25-002576
Form type
SCHEDULE 13G/A
Filer
4D Molecular Therapeutics, Inc.
CIK
CIK 1650648
Filed
Oct 17, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub